GSK
713 hedge funds and large institutions have $14.4B invested in GSK in 2014 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 285 increasing their positions, 212 reducing their positions, and 34 closing their positions.
109% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 34
70% more call options, than puts
Call options by funds: $117M | Put options by funds: $69.2M
34% more repeat investments, than reductions
Existing positions increased: 285 | Existing positions reduced: 212
5% more funds holding
Funds holding: 682 → 713 (+31)
0% more capital invested
Capital invested by funds: $14.3B → $14.4B (+$35.1M)
0.01% more ownership
Funds ownership: 4.42% → 4.43% (+0.01%)
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$233M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$40.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.1M |
| 4 |
Renaissance Technologies
New York
|
+$31.6M |
| 5 |
Goldman Sachs
New York
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$213M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$138M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$67.9M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$61.1M |
| 5 |
Primecap Management
Pasadena,
California
|
-$44.4M |
GSK Hedge Fund Activity: Q1 2014 in Review
713 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2014, worth a combined $14.4B — up 0.24% from $14.3B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new GSK positions and 34 closed out — a net gain of 37 holders — while 285 added to existing stakes and 212 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $233M. The largest seller was Royal Bank of Canada, cutting an estimated $213M.
- 713 institutional investors held GSK (GSK) as of Q1 2014, up from 682 in Q4 2013.
- Funds reported $14.4B of GSK stock for Q1 2014, up 0.24% quarter-over-quarter.
- 71 funds opened new GSK positions in Q1 2014 and 34 closed out, a net change of +37 holders.
- The largest GSK buyer in Q1 2014 was Arrowstreet Capital, an estimated $233M added.
- The largest GSK seller in Q1 2014 was Royal Bank of Canada, an estimated $213M sold.
Based on aggregated 13F filings for Q1 2014.